Literature DB >> 18692468

p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.

Andrei V Budanov1, Michael Karin.   

Abstract

The tumor suppressor p53 is activated upon genotoxic and oxidative stress and in turn inhibits cell proliferation and growth through induction of specific target genes. Cell growth is positively regulated by mTOR, whose activity is inhibited by the TSC1:TSC2 complex. Although genotoxic stress has been suggested to inhibit mTOR via p53-mediated activation of mTOR inhibitors, the precise mechanism of this link was unknown. We now demonstrate that the products of two p53 target genes, Sestrin1 and Sestrin2, activate the AMP-responsive protein kinase (AMPK) and target it to phosphorylate TSC2 and stimulate its GAP activity, thereby inhibiting mTOR. Correspondingly, Sestrin2-deficient mice fail to inhibit mTOR signaling upon genotoxic challenge. Sestrin1 and Sestrin2 therefore provide an important link between genotoxic stress, p53 and the mTOR signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692468      PMCID: PMC2758522          DOI: 10.1016/j.cell.2008.06.028

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  50 in total

Review 1.  Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways.

Authors:  Arnold J Levine; Zhaohui Feng; Tak W Mak; Han You; Shengkan Jin
Journal:  Genes Dev       Date:  2006-02-01       Impact factor: 11.361

Review 2.  TOR signaling in growth and metabolism.

Authors:  Stephan Wullschleger; Robbie Loewith; Michael N Hall
Journal:  Cell       Date:  2006-02-10       Impact factor: 41.582

3.  PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes.

Authors:  S Velasco-Miguel; L Buckbinder; P Jean; L Gelbert; R Talbott; J Laidlaw; B Seizinger; N Kley
Journal:  Oncogene       Date:  1999-01-07       Impact factor: 9.867

Review 4.  Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

Authors:  M N Corradetti; K-L Guan
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

Review 5.  Genomic instability in 1p and human malignancies.

Authors:  M Schwab; C Praml; L C Amler
Journal:  Genes Chromosomes Cancer       Date:  1996-08       Impact factor: 5.006

Review 6.  The mammalian target of rapamycin signaling network and gene regulation.

Authors:  Ghada A Soliman
Journal:  Curr Opin Lipidol       Date:  2005-06       Impact factor: 4.776

7.  mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E.

Authors:  Diane C Fingar; Celeste J Richardson; Andrew R Tee; Lynn Cheatham; Christina Tsou; John Blenis
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

Review 8.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.

Authors:  Diane C Fingar; John Blenis
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

9.  eIF4E--from translation to transformation.

Authors:  Yaël Mamane; Emmanuel Petroulakis; Liwei Rong; Kaori Yoshida; Lian Wee Ler; Nahum Sonenberg
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

10.  Protein kinase C-mediated down-regulation of cyclin D1 involves activation of the translational repressor 4E-BP1 via a phosphoinositide 3-kinase/Akt-independent, protein phosphatase 2A-dependent mechanism in intestinal epithelial cells.

Authors:  Lingjie Guan; Kyung Song; Marybeth A Pysz; Kathryn J Curry; A Asli Hizli; David Danielpour; Adrian R Black; Jennifer D Black
Journal:  J Biol Chem       Date:  2007-03-13       Impact factor: 5.157

View more
  585 in total

1.  Escherichia coli succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding.

Authors:  C M Bowman; J S Nishimura
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

2.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress.

Authors:  Sang-Min Jeon; Navdeep S Chandel; Nissim Hay
Journal:  Nature       Date:  2012-05-09       Impact factor: 49.962

3.  Coupled activation and degradation of eEF2K regulates protein synthesis in response to genotoxic stress.

Authors:  Flore Kruiswijk; Laurensia Yuniati; Roberto Magliozzi; Teck Yew Low; Ratna Lim; Renske Bolder; Shabaz Mohammed; Christopher G Proud; Albert J R Heck; Michele Pagano; Daniele Guardavaccaro
Journal:  Sci Signal       Date:  2012-06-05       Impact factor: 8.192

Review 4.  Deconvoluting mTOR biology.

Authors:  Jason D Weber; David H Gutmann
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 5.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

6.  Regulation of mast cell survival and function by tuberous sclerosis complex 1.

Authors:  Jinwook Shin; Hongjie Pan; Xiao-Ping Zhong
Journal:  Blood       Date:  2012-02-23       Impact factor: 22.113

Review 7.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.

Authors:  L Ouyang; Z Shi; S Zhao; F-T Wang; T-T Zhou; B Liu; J-K Bao
Journal:  Cell Prolif       Date:  2012-10-03       Impact factor: 6.831

Review 8.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

9.  Induction of SOX4 by DNA damage is critical for p53 stabilization and function.

Authors:  Xin Pan; Jie Zhao; Wei-Na Zhang; Hui-Yan Li; Rui Mu; Tao Zhou; Hai-Ying Zhang; Wei-Li Gong; Ming Yu; Jiang-Hong Man; Pei-Jing Zhang; Ai-Ling Li; Xue-Min Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

10.  p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.

Authors:  Stuti Agarwal; Catherine M Bell; Shirley M Taylor; Richard G Moran
Journal:  Mol Cancer Res       Date:  2015-09-18       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.